IRG1/Itaconate induces metabolic reprogramming to suppress ER-positive breast cancer cell growth.
Hsueh‐Chun Wang(China Medical University), Mien‐Chie Hung(Precision Therapeutics (United States))
PubMed
January 1, 2023
Cited by 12
Related Papers
PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients
|Cancer Cell|2004|1.9k
Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity
|Nature Communications|2016|1.1k
STT3-dependent PD-L1 accumulation on cancer stem cells promotes immune evasion
|Nature Communications|2018|427
IL-6/JAK1 pathway drives PD-L1 Y112 phosphorylation to promote cancer immune evasion
|Journal of Clinical Investigation|2019|380